Comparison of centchroman and PPIUCD in terms of efficacy, safety and continuation rate in immediate postpartum period

Authors

  • Megha Gupta Department of Obstetrics and Gynecology, VMMC and Safdarjung Hospital, Delhi, India
  • Reeta Bansiwal Department of Obstetrics and Gynecology, VMMC and Safdarjung Hospital, Delhi, India
  • H. P. Anand Department of Obstetrics and Gynecology, VMMC and Safdarjung Hospital, Delhi, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20205769

Keywords:

Centchroman, Continuation rate, PPIUCD, Safety, Satisfaction rate

Abstract

Background: Study was done to assess the efficacy, safety and continuation rate of Centchroman and IUCD administered in immediate postpartum period (within 48 hours).

Methods: An interventional study was conducted in Obstetrics and Gynecology department of Safdarjung Hospital, New Delhi, at a tertiary care hospital after approval from ethical committee. 280 women were enrolled in the study and divided into 2 groups centchroman group and PPIUCD group, 140 in each group after excluding the exclusion criteria and satisfying inclusion criteria. These women were followed up at 6 week, 3 month and 6 months to study efficacy, safety and continuation rate.

Results: Centchroman as contraception is safe with fewer side effects, better satisfaction rate and better continuation rate in comparison to PPIUCD.

Conclusions: Centchroman is a newer contraceptive which is recently added in basket of family planning in our country to give wider choices to women. It is an indigenous product developed by central drug research institute (CDRI), Lucknow available free of cost in government hospitals. Centchroman needs more popularity and education for its widespread use.

Author Biography

Megha Gupta, Department of Obstetrics and Gynecology, VMMC and Safdarjung Hospital, Delhi, India

vardhman mahavir medical college and safdarjung hospital

References

India at Glance Population census 2011. Census organization of India, 2011. Available at http:// censusindia.gov. in/ 2011-prov- results /india at glance. html. Accessed on 25 August 2017.

IUCD reference manual for medical officers and nursing personal: Family Planning Division, Ministry of Health and Family Welfare, Government of India 2013. Available at http:// www. nrhmtn. gov.in/modules/IUCD_Reference_Manual_for_MOs_and_Nursing_Personne_-Final-Sept_2013:1-15. Accesed on 20 August 2017.

Park K. Social and Preventive Medicine. 23rd ed. Jabalpur: Banarsidas bhanot; 2015:437-440.

Counselling for postpartum family planning and immediate postpartum iucd reference manual 2011. Available at http:// reprolineplus. org/ system/ files/resources/PPFP_PPIUCD_Counseling_Manual_draft. chapter 1:1-8. Accessed on 15 September 2017.

Kamboj VP, Ray S, Anand N. Centchroman: a safe reversible postcoital contraceptive with curative and prophylactic activity in many disorders. Frontiers Biosci Elite. 2018;10:1-14.

Nair HS, Jayasimhan P. A prospective study of centchroman users with special reference to its contraceptive benefit. J Evid Based Med Healthc. 2016;3:5374-80.

Smith J, Muthoni J, Das V. International conference on family planning: research and best practice. 2009:15-18.

Agrawal P, Kushwa V, Mangal BK. Evaluation of safety profile of centchroman for contraceptive purpose. National J Allied Sci. 2016;5:41-4.

Celen S, Moroy P, Sucak A, Aktulay A, Danisman N. Clinical outcome of early post placental insertion of intrauterine contraceptive devices. Contraception. 2004;69:279-82.

Barala S, Maheshwari S, Sharma P. Analysis of awareness, acceptance, safety and continuation rate of post-placental and intra-caesarean insertion of intrauterine contraceptive device. Int J Reprod Contracept Obstet Gynecol. 2016;5:1974-80.

Downloads

Published

2020-12-26

Issue

Section

Original Research Articles